Massachusetts-based Jade Biosciences (Nasdaq: JBIO), registered a first-in-human Phase I trial of JADE201, an afucosylated, Fc-engineered anti-BAFF-R monoclonal antibody, in adults with rheumatoid arthritis. The study, listed on ClinicalTrials.gov as NCT07533955, is scheduled to begin enrollment in May 2026 at sites in Moldova and Ukraine.
JADE201 targets the B-cell activating factor receptor (BAFF-R), a pathway with prior clinical validation, but applies a molecular engineering strategy — combining afucosylation for enhanced antibody-dependent cellular cytotoxicity with an Fc point mutation to extend half-life via the neonatal Fc receptor. The company states this design helps improve on the depth and durability of B-cell depletion achieved by earlier agents in the class.
The Phase I study is randomized, double-blind, and placebo-controlled, enrolling approximately 36 participants across six sequential dose cohorts. Participants must have a confirmed rheumatoid arthritis diagnosis per 2010 ACR/EULAR criteria and fall within defined body weight and BMI ranges. The primary objective is to characterize the safety and tolerability of single ascending subcutaneous doses over a 36-week observation window, with secondary endpoints capturing the pharmacokinetic profile — including peak serum concentration, terminal half-life, and area under the concentration-time curve. Primary completion is projected for Q4 2027, with full study completion in Q4 2028.
The BAFF-R pathway
The BAFF-R pathway has been under active clinical investigation for over a decade. BAFF (B-cell activating factor, also known as BLyS) promotes survival, maturation, and proliferation of B cells by signaling through BAFF-R, a receptor expressed predominantly on mature B cells. In autoimmune conditions including rheumatoid arthritis, elevated BAFF levels sustain autoreactive B-cell populations that contribute to synovial inflammation and joint destruction. Blocking or eliminating BAFF-R-expressing B cells has therefore been a rational therapeutic target, with the logic that more complete B-cell depletion could translate to deeper and more durable disease control than is achieved by agents that act downstream or on different immune compartments.